<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phentermine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phentermine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phentermine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11271" href="/d/html/11271.html" rel="external">see "Phentermine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="140793" href="/d/html/140793.html" rel="external">see "Phentermine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F209145"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Adipex-P;</li>
<li>Lomaira</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867922"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>RHO-Phentermine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F209168"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anorexiant;</li>
<li>
                        Central Nervous System Stimulant;</li>
<li>
                        Sympathomimetic</li></ul></div>
<div class="block doa drugH1Div" id="F209150"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="033e16dc-3c33-45cf-bc8f-1c6bbee06e76">Weight management, short-term</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, short-term (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid in patients with heart disease, poorly controlled hypertension, pulmonary hypertension, or history of substance use disorder or drug abuse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Perreault.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Perreault.1'])">Ref</a></span>). For short-term use (up to 12 weeks) as an adjunct to diet and exercise in patients who cannot take preferred agents and who have a BMI ≥30 kg/m<sup>2</sup>
<b>or</b> patients with a BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-associated comorbidity (eg, dyslipidemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27219496','lexi-content-ref-25590212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27219496','lexi-content-ref-25590212'])">Ref</a></span>). Some experts use long-term in select patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36273831','lexi-content-ref-25590212']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36273831','lexi-content-ref-25590212'])">Ref</a></span>). Dosing is presented in terms of the salt, phentermine hydrochloride (not as phentermine base).</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule, tablet (excluding Lomaira): <b>Oral:</b> 15 to 37.5 mg once daily before breakfast or 1 to 2 hours after breakfast; in some cases, may administer 18.75 mg once or twice daily using the tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (Lomaira only): <b>Ora</b>l: 8 mg 3 times daily 30 minutes before meals.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990920"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Capsule, tablet (excluding Lomaira):</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 15 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Avoid use (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease (ESRD) requiring dialysis: Avoid use (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Tablet (Lomaira only):</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); systemic exposure may be increased; use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988202"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F209151"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F4092487"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="140793" href="/d/html/140793.html" rel="external">see "Phentermine: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing is presented in terms of phentermine hydrochloride salt, not as phentermine base. Phentermine is available as 2 products (Adipex-P, Lomaira) which have unique dosing.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="033e16dc-3c33-45cf-bc8f-1c6bbee06e76">Weight management, short-term</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, short-term: Note: </b>For short-term use (up to 12 weeks) as an adjunct to diet and exercise in patients who cannot take preferred agents and who have a BMI ≥30 kg/m<sup>2</sup> or patients with a BMI ≥27 kg/m<sup>2</sup> and ≥1 weight-associated comorbidity (eg, dyslipidemia, diabetes mellitus, hypertension). Dose should be individualized to lowest effective dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: <b></b></p>
<p style="text-indent:-2em;margin-left:6em;">Adipex-P: Capsule, tablet: Oral: Usual dose: 37.5 mg once daily before breakfast or 1 to 2 hours after breakfast; with the tablet dosage form, a dose of 18.75 mg (<sup>1</sup>/<sub>2</sub> tablet) once or twice daily may be appropriate in some cases.</p>
<p style="text-indent:-2em;margin-left:6em;">Lomaira: Tablet: Oral: 8 mg 3 times daily 30 minutes before meals; in some cases, 4 mg (<sup>1</sup>/<sub>2</sub> tablet) may be appropriate.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information. <b></b></p></div>
<div class="block dorp drugH1Div" id="F51153478"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Adolescents ≥17 years:</p>
<p style="text-indent:-2em;margin-left:4em;">Adipex-P: Capsule, tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; systemic exposure may be increased; use with caution.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: Maximum daily dose: 15 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Avoid use (has not been studied).</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage renal disease (ESRD) requiring dialysis: Avoid use (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Lomaira: Tablet: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); systemic exposure may be increased; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51153479"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥17 years: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56425259"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Data regarding the cardiac effects of phentermine alone are limited and conflicting; available evidence suggests that cardiac effects are rare (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22363917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22363917'])">Ref</a></span>). Phentermine alone may cause <b>increased blood pressure</b> and<b> tachycardia</b>; arrhythmias (including <b>prolonged QT interval on ECG</b>, <b>supraventricular tachycardia</b>, <b>ventricular tachycardia</b> [polymorphic], and <b>ventricular fibrillation</b>); <b>cardiomyopathy</b> (atrial fibrillation-induced); and <b>acute myocardial infarction</b> have been reported in patients with no history of cardiovascular disease (CVD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33686912','lexi-content-ref-31272579','lexi-content-ref-23076689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33686912','lexi-content-ref-31272579','lexi-content-ref-23076689'])">Ref</a></span>). One study suggests that phentermine may not increase blood pressure long-term (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26934640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26934640'])">Ref</a></span>). Historically, serious regurgitant valvular heart disease (primarily affecting the mitral, aortic, and/or tricuspid valves) has been reported in patients receiving a combination of phentermine and fenfluramine or dexfenfluramine (combination removed from market) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9271479','lexi-content-ref-10755496','lexi-content-ref-16808550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9271479','lexi-content-ref-10755496','lexi-content-ref-16808550'])">Ref</a></span>); rare cases of valvular heart disease with the use of phentermine alone have been reported to the FDA, and the possibility of an association cannot be ruled out. In a descriptive analysis using the FDA Adverse Event Reporting System (FAERS) databases, cardiovascular adverse reactions (unspecified) with phentermine accounted for 31% (n=542) of the total adverse reactions reported among all anti-obesity mediations between 2013 to 2020; the baseline CVD risk of the patients associated with these reports is unknown. In addition, due to limitations related to reporting, these data do not prove cause but rather suggest potential risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34564826']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34564826'])">Ref</a></span>). Conversely, one retrospective study showed no increased risk of incident CVD or death in patients with no history of CVD who were taking phentermine alone for &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; possibly due to coronary artery vasospasm related to increased adrenergic activity from phentermine, primarily via norepinephrine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31272562','lexi-content-ref-33686912','lexi-content-ref-31272579','lexi-content-ref-23076689']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31272562','lexi-content-ref-33686912','lexi-content-ref-31272579','lexi-content-ref-23076689'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Phentermine (alone and in combination) has been associated with CNS effects, including delirium, mania, and <b>psychosis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9501893','lexi-content-ref-29955552','lexi-content-ref-30690949','lexi-content-ref-9137134','lexi-content-ref-9714271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9501893','lexi-content-ref-29955552','lexi-content-ref-30690949','lexi-content-ref-9137134','lexi-content-ref-9714271'])">Ref</a></span>). Literature has reported <b>insomnia</b>, <b>irritability</b>, and <b>anxiety</b> in 24% to 27% of users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24231879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24231879'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action; stimulates release of norepinephrine and dopamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8924191','lexi-content-ref-30690949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8924191','lexi-content-ref-30690949'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically occurs within 1 week of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21595510','lexi-content-ref-29955552','lexi-content-ref-9714271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21595510','lexi-content-ref-29955552','lexi-content-ref-9714271'])">Ref</a></span>) but may occur several months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8959483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8959483'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (112.5 to 150 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30690949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30690949'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Personal or family history of psychiatric disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9501893','lexi-content-ref-8959483','lexi-content-ref-9137134']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9501893','lexi-content-ref-8959483','lexi-content-ref-9137134'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Primary pulmonary hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary pulmonary hypertension</b> (PPH) has been reported in patients receiving a combination of phentermine and fenfluramine or dexfenfluramine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32152496','lexi-content-ref-11834685']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32152496','lexi-content-ref-11834685'])">Ref</a></span>). The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; at least one case has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20879069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20879069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; related to the pharmacologic action; hypothesized to be due to an increased 5-HT and subsequent vascular remodeling (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11806844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11806844'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed. In a case report with phentermine alone, onset of PPH occurred 3 months after the use of phentermine for 5 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20879069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20879069'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of use &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16808550']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16808550'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F209123"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased blood pressure, ischemia, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dysphoria, euphoria, overstimulation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Prasad 2019), cardiomyopathy (atrial fibrillation-induced) (Kumar 2021), prolonged QT interval on ECG (Kumar 2021), supraventricular tachycardia (Kumar 2021), tachycardia (Yanovski 2014), ventricular fibrillation (Kumar 2021; Tobbia 2012), ventricular tachycardia (polymorphic) (Kumar 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (Yanovski 2014), diarrhea (Yanovski 2014), gastrointestinal distress (Yanovski 2014), unpleasant taste (Yanovski 2014), xerostomia (Yanovski 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (Yanovski 2014), cerebral hemorrhage (McNeil 2018), dizziness (Yanovski 2014), headache (Yanovski 2014), insomnia (Yanovski 2014), irritability (Yanovski 2014), psychosis (Jo 2019), restlessness (Yanovski 2014), tremor (Yanovski 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Shao 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Primary pulmonary hypertension (Bang 2010)</p></div>
<div class="block coi drugH1Div" id="F209136"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity or idiosyncrasy to phentermine, other sympathomimetic amines or any component of the formulation; history of cardiovascular disease (eg, arrhythmias, heart failure, coronary artery disease, stroke, uncontrolled hypertension); hyperthyroidism; glaucoma; agitated states; history of drug abuse; use during or within 14 days following MAO inhibitor therapy; pregnancy; breastfeeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F209120"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Avoid stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry. Use with caution in patients with mild hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; antidiabetic agent requirements (eg, insulin or oral hypoglycemic agents) may be decreased with anorexigens and concomitant dietary restrictions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use caution in patients with renal impairment; an increase in exposure is expected. Avoid use in patients with eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>, including end-stage renal disease (ESRD) requiring dialysis (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Avoid or use with caution in patients with history of seizures (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tourette syndrome: Use with caution in patients with Tourette syndrome; stimulants may unmask tics.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use caution in this age group due to the risk for causing dependence, hypertension, angina, and myocardial infarction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse potential: Phentermine is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Tolerance to the anorectic effect usually develops within a few weeks; discontinue use when tolerance develops, do not exceed recommended dosage in an attempt to overcome tolerance.</p></div>
<div class="block foc drugH1Div" id="F209131"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adipex-P: 37.5 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg, 37.5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adipex-P: 37.5 mg [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adipex-P: 37.5 mg [DSC] [contains corn starch, fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lomaira: 8 mg [scored; contains corn starch, fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 37.5 mg</p></div>
<div class="block geq drugH1Div" id="F209116"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F209138"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Phentermine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $0.34 - $1.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.48 - $1.32</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $0.33 - $1.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Adipex-P Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $2.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lomaira Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg (per each): $0.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Phentermine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">37.5 mg (per each): $0.19 - $1.54</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867923"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 mg, 30 mg</p></div>
<div class="block csi drugH1Div" id="F209170"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F4092489"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Avoid late evening administration. Most effective when combined with a low-calorie diet and behavior modification counseling.</p>
<p style="text-indent:-2em;margin-left:2em;">Capsules, tablets (excluding Lomaira): Administer before breakfast or 1 to 2 hours after breakfast. Tablets may be divided in half and dose may be given in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet (Lomaira only): Administer 30 minutes before meals. Tablets are scored and may be divided in half.</p></div>
<div class="block admp drugH1Div" id="F52613579"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Avoid late evening administration. Scored tablets may be cut in half to achieve dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Adipex-P: Administer before breakfast or 1 to 2 hours after breakfast.</p>
<p style="text-indent:-2em;margin-left:2em;">Lomaira: Administer 30 minutes before meals.</p></div>
<div class="block use drugH1Div" id="F209132"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Weight management, short-term:</b> Short-term (few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity with an initial body mass index ≥30 kg/m<sup>2</sup> or ≥27 kg/m<sup>2</sup> in the presence of other risk factors (eg, diabetes, hyperlipidemia, controlled hypertension). <b>Note: </b>Some experts use long-term in select patients (ES [Apovian 2015]).</p></div>
<div class="block mst drugH1Div" id="F209177"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Phentermine may be confused with phentolamine, phenytoin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299866"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F209125"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Phentermine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May decrease the excretion of Amphetamines. Management: Consider alternatives to using amphetamines and alkalinizing agents in combination. If these agents must be used together, patients should be monitored closely for excessive amphetamine effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: Amphetamines may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: May enhance the adverse/toxic effect of Amphetamines. Antipsychotic Agents may diminish the stimulatory effect of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Bromperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a strong CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of CNS Stimulants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Amphetamines may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: CNS Stimulants may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Phentermine may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Amphetamines may enhance the analgesic effect of Opioid Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Amphetamines may enhance the cardiotoxic effect of Quinolones. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors): Amphetamines may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities, including serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust dose as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Amphetamines may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sibutramine: May enhance the adverse/toxic effect of Centrally Acting Weight Loss Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Amphetamines. Tricyclic Antidepressants may potentiate the cardiovascular effects of Amphetamines. Amphetamines may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased cardiovascular effects when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Amphetamines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54208205"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Phentermine was evaluated in patients with infertility and overweight/obesity. Patients in the single center retrospective study (n=55) used contraception during therapy and were instructed to stop phentermine 1 month prior to trying to conceive. Although patients treated with phentermine had significant weight loss, pregnancy and live birth rates were not increased between patients who lost &lt;5% or &gt;5% of their initial body weight (Chang 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Obesity increases the risk of infertility. Optimal weight control prior to conception improves pregnancy outcomes. However, medications for weight loss are not recommended prior to pregnancy due to safety issues and adverse events. Weight loss medications should be discontinued prior to conception (ACOG 2021; Wharton 2020).</p></div>
<div class="block pri drugH1Div" id="F4104669"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of phentermine during pregnancy is limited (D'Adesky 2019; Jones 2002; McElhatton 2006).</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of adverse maternal and fetal events is associated with obesity. However, moderate gestational weight gain based on pre-pregnancy BMI is required for positive fetal outcomes in all pregnancies, including patients with overweight or obesity. Therefore, medications for weight loss therapy are not recommended during pregnancy (ACOG 2021; Wharton 2020). Use of phentermine is contraindicated during pregnancy (lack of potential benefit and possible fetal harm).</p></div>
<div class="block brc drugH1Div" id="F10515287"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if phentermine is present in breast milk; however, other amphetamines have been detected in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to safety concerns, medications for weight loss therapy are not recommended for patients who are breastfeeding (Wharton 2020). Use of phentermine is contraindicated in breastfeeding patients.</p></div>
<div class="block dic drugH1Div" id="F4092488"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules, tablets (excluding Lomaira): Should be taken before breakfast or 1 to 2 hours after breakfast.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet (Lomaira only): Should be taken 30 minutes before meals.</p></div>
<div class="block mop drugH1Div" id="F209128"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Weight and waist circumference every month for the first 3 months, then at 3-month intervals (Apovian 2015); BP; CNS effects (eg, delirium, mania, psychosis); signs/symptoms of primary pulmonary hypertension (eg, new-onset dyspnea, chest pain, syncope, lower extremity edema).</p></div>
<div class="block rer drugH1Div" id="F4092486"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Adult classification of weight by BMI (kg/m<sup>2</sup>):</p>
<p style="text-indent:-2em;margin-left:4em;">Underweight: &lt;18.5</p>
<p style="text-indent:-2em;margin-left:4em;">Normal: 18.5 to 24.9</p>
<p style="text-indent:-2em;margin-left:4em;">Overweight: 25 to 29.9</p>
<p style="text-indent:-2em;margin-left:4em;">Obesity, class I: 30 to 34.9</p>
<p style="text-indent:-2em;margin-left:4em;">Obesity, class II: 35 to 39.9</p>
<p style="text-indent:-2em;margin-left:4em;">Obesity, class III: ≥40</p>
<p style="text-indent:-2em;margin-left:2em;">Waist circumference: In adults with a BMI of 25 to 34.9 kg/m<sup>2</sup>, high-risk waist circumference is defined as:</p>
<p style="text-indent:-2em;margin-left:4em;">Males &gt;102 cm (&gt;40 in).</p>
<p style="text-indent:-2em;margin-left:4em;">Females &gt;88 cm (&gt;35 in).</p></div>
<div class="block pha drugH1Div" id="F209119"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Phentermine is a sympathomimetic amine with pharmacologic properties similar to the amphetamines. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine.</p></div>
<div class="block phk drugH1Div" id="F209135"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 348 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 17.5%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via p-hydroxylation (aromatic ring) and N-oxidation (aliphatic side chain); primarily metabolized by CYP3A4 (but does not show extensive metabolism).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~20 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 3 to 4.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily urine (62% to 85% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51198720"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Exposure increases can be expected in patients with renal impairment.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F209139"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alenami | Duromine | Metermine | Phentermine gh | Phentermine juno er | Phentodur</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ionamin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Ionamine | Normaform</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Compulxine | Duromine | Fentex | Finapet | Obexol | Sentis</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Mirapront</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Obexol | Supress p | Terfamex</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Obexol | Sentis</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mirapront</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Ionamin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Panbesy | Phentermine | Redusa</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Adipex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Mirapront</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ionamin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Novirasin | Razin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Artmin | Bm zine | Bmzine | Daehwa nobse | Dietamin | Festin | Furimin | Hanbul phentermin | Hutermin | Hutermine semi | Lediphen | Metamax | Panbesi | Panbesy | Pender | Penimin | Penmin | Pentazen | Pentmin | Phedin | Phenkini | Phentazen | Phentazia | Phentemy | Phentermine | Ptm | Retis | Sinsphen | Slemin | Tintin | Weltmine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Mirapront</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ionamine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Mirapront</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acxion | Acxion ap | Acxion c | Definitum | Disebsin | Fentermina | Ifa acxion | Ifa-reduccing s | Ina10 | Novagrit | Raamcaps | Reducap | Sinpet | Terfamex | Terfamex od</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Adipex | Axcel phentermine | Duromine | Ionamin | Panbesy</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Adipex-p</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Metermine | Umine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Obexol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Ionamin | Phentermine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Mirapront</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Adipex-p | Fastin | Ionamin | Lomaira | Phentermine HCL</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Obexol | Sentis | Terfamex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Ionamin | Panbesy | Umine</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Adipex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Ionamin | Mirapront | Panbesy | Phentermine</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mirubal</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Duromine | Minex | Minobese | Musalos | Panbesy</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AdipexP.2020.09">
<a name="AdipexP.2020.09"></a>Adipex-P (phentermine) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21595510">
<a name="21595510"></a>Alexander J, Cheng YH, Choudhary J, Dinesh A. Phentermine (Duromine) precipitated psychosis. <i>Aust N Z J Psychiatry</i>. 2011;45(8):684-685. doi:10.3109/00048674.2011.580721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/21595510/pubmed" id="21595510" target="_blank">21595510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34564826">
<a name="34564826"></a>Alsuhibani A, Alrasheed M, Gari M, Hincapie AL, Guo JJ. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020. <i>Int J Clin Pharm</i>. 2022;44(1):172-179. doi:10.1007/s11096-021-01330-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/34564826/pubmed" id="34564826" target="_blank">34564826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011890">
<a name="34011890"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 230: Obesity in pregnancy. <i>Obstet Gynecol</i>. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/34011890/pubmed" id="34011890" target="_blank">34011890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi:10.1210/jc.2014-3415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9501893">
<a name="9501893"></a>Bagri S, Reddy G. Delirium with manic symptoms induced by diet pills. <i>J Clin Psychiatry</i>. 1998;59(2):83. doi:10.4088/jcp.v59n0207d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/9501893/pubmed" id="9501893" target="_blank">9501893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20879069">
<a name="20879069"></a>Bang WD, Kim JY, Yu HT, et al. Pulmonary hypertension associated with use of phentermine. <i>Yonsei Med J</i>. 2010;51(6):971-973. doi:10.3349/ymj.2010.51.6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/20879069/pubmed" id="20879069" target="_blank">20879069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8924191">
<a name="8924191"></a>Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. <i>Neuropsychopharmacology</i>. 1996;14(4):233-241. doi:10.1016/0893-133X(95)00113-R<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/8924191/pubmed" id="8924191" target="_blank">8924191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33471704">
<a name="33471704"></a>Chang JJ, Lathi RB, Kim SH. A retrospective study examining phentermine on preconception weight loss and pregnancy outcomes. <i>Endocr Pract</i>. 2020;26(9):990-996. doi:10.4158/EP-2019-0609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/33471704/pubmed" id="33471704" target="_blank">33471704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8959483">
<a name="8959483"></a>Cleare AJ. Phentermine, psychosis, and family history.<i> J Clin Psychopharmacol</i>. 1996;16(6):470-471. doi:10.1097/00004714-199612000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/8959483/pubmed" id="8959483" target="_blank">8959483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9271479">
<a name="9271479"></a>Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. <i>N Engl J Med</i>. 1997;337(9):581-588. doi:10.1056/NEJM199708283370901. Erratum in: <i>N Engl J Med. </i>1997;337(24):1783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/9271479/pubmed" id="9271479" target="_blank">9271479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31890378">
<a name="31890378"></a>D'Adesky N, Ghosh S. Phentermine use during first and second trimesters associated with fetal stroke. <i>Cureus</i>. 2019;11(11):e6170. doi:10.7759/cureus.6170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/31890378/pubmed" id="31890378" target="_blank">31890378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11806844">
<a name="11806844"></a>Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. <i>Respir Res</i>. 2002;3(1):9. doi:10.1186/rr181<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/11806844/pubmed" id="11806844" target="_blank">11806844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31272562">
<a name="31272562"></a>Franke KB, Psaltis PJ. Coronary vasospasm induced by phentermine. <i>Mayo Clin Proc</i>. 2019;94(7):1138-1140. doi:10.1016/j.mayocp.2019.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/31272562/pubmed" id="31272562" target="_blank">31272562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755496">
<a name="10755496"></a>Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. <i>JAMA</i>. 2000;283(13):1703-1709. doi:10.1001/jama.283.13.1703<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/10755496/pubmed" id="10755496" target="_blank">10755496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27219496">
<a name="27219496"></a>Garvey WT, Mechanick JI, Brett EM, et al; reviewers of the AACE/ACE obesity clinical practice guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. <i>Endocr Pract</i>. 2016;22(suppl 3):1-203. doi:10.4158/EP161365.GL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/27219496/pubmed" id="27219496" target="_blank">27219496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32152496">
<a name="32152496"></a>Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. <i>Int J Obes (Lond)</i>. 2020;44(5):1021-1027. doi:10.1038/s41366-020-0544-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/32152496/pubmed" id="32152496" target="_blank">32152496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36273831">
<a name="36273831"></a>Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. <i>Gastroenterology</i>. 2022;163(5):1198-1225. doi:10.1053/j.gastro.2022.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/36273831/pubmed" id="36273831" target="_blank">36273831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955552">
<a name="29955552"></a>Homola J, Hieber R. Combination of venlafaxine and phentermine/topiramate induced psychosis: a case report. <i>Ment Health Clin</i>. 2018;8(2):95-99. doi:10.9740/mhc.2018.03.095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/29955552/pubmed" id="29955552" target="_blank">29955552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16984841">
<a name="16984841"></a>Hung YM, Chang JC. Weight-reducing regimen associated with polymorphic ventricular tachycardia. <i>Am J Emerg Med</i>. 2006;24(6):714-716. doi:10.1016/j.ajem.2006.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/16984841/pubmed" id="16984841" target="_blank">16984841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30690949">
<a name="30690949"></a>Jo HS, Wang SM, Kim JJ. Recurrent psychosis after phentermine administration in a young female: a case report. <i>Clin Psychopharmacol Neurosci</i>. 2019;17(1):130-133. doi:10.9758/cpn.2019.17.1.130<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/30690949/pubmed" id="30690949" target="_blank">30690949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11877776">
<a name="11877776"></a>Jones KL, Johnson KA, Dick LM, Felix RJ, Kao KK, Chambers CD. Pregnancy outcomes after first trimester exposure to phentermine/fenfluramine. <i>Teratology</i>. 2002;65(3):125-130. doi:10.1002/tera.10023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/11877776/pubmed" id="11877776" target="_blank">11877776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22363917">
<a name="22363917"></a>Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. <i>Diabetes Metab J</i>. 2012;36(1):13-25. doi:10.4093/dmj.2012.36.1.13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/22363917/pubmed" id="22363917" target="_blank">22363917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33686912">
<a name="33686912"></a>Kumar S, Mogalapalli A, Srinivasamurthy R, Hussain ST, Mar PL. Supraventricular tachycardia with the use of phentermine: case report and review of literature. <i>Postgrad Med</i>. 2021;133(4):454-457. doi:10.1080/00325481.2021.1901476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/33686912/pubmed" id="33686912" target="_blank">33686912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900410">
<a name="30900410"></a>Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. <i>Obesity (Silver Spring)</i>. 2019;27(4):591-602. doi:10.1002/oby.22430<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/30900410/pubmed" id="30900410" target="_blank">30900410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lomaira.2016.09">
<a name="Lomaira.2016.09"></a>Lomaira (phentermine) [prescribing information]. Newtown, PA: KVK-Tech; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McElhatton.2006">
<a name="McElhatton.2006"></a>McElhatton P, Stephens S. Preliminary data on pregnancy outcome following exposure to drugs for the treatment of obesity In pregnancy. 34th Annual Conference of the European Teratology Society, 3rd–6th September 2006, Abano Terme, Padova, Italy. <i>Reprod Toxicol</i>. 2006;22(2):277-278.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30179740">
<a name="30179740"></a>McNeill S, Almallouhi E, Lowe FJ, Turan TN. Phentermine associated recurrent intracerebral hemorrhage. <i>J Neurol Sci.</i> 2018;393:135-137. doi:10.1016/j.jns.2018.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/30179740/pubmed" id="30179740" target="_blank">30179740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perreault.1">
<a name="Perreault.1"></a>Perreault L. Obesity in adults: drug therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 11, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phentermine.2013.01">
<a name="Phentermine.2013.01"></a>Phentermine hydrochloride capsules [prescribing information]. Sellersville, PA: Teva Pharmaceuticals; January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31272579">
<a name="31272579"></a>Prasad M, El Sabbagh A, Rihal C, Lerman A. Phentermine and coronary vasospasm-induced myocardial infarction. <i>Mayo Clin Proc</i>. 2019;94(7):1374-1377. doi:10.1016/j.mayocp.2018.08.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/31272579/pubmed" id="31272579" target="_blank">31272579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qsymia.2013.04">
<a name="Qsymia.2013.04"></a>Qsymia (phentermine and topiramate) [prescribing information]. Winchester, KY: Vivus Inc; April 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9137134">
<a name="9137134"></a>Raison CL, Klein HM. Psychotic mania associated with fenfluramine and phentermine use. <i>Am J Psychiatry</i>. 1997;154(5):711. doi:10.1176/ajp.154.5.711a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/9137134/pubmed" id="9137134" target="_blank">9137134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28280086">
<a name="28280086"></a>Shao EX, Wilson GJ, Ranganathan D. Phentermine induced acute interstitial nephritis. <i>BMJ Case Rep</i>. 2017;2017:bcr2017219452. doi:10.1136/bcr-2017-219452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/28280086/pubmed" id="28280086" target="_blank">28280086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934640">
<a name="26934640"></a>Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension. <i>Cochrane Database Syst Rev</i>. 2016;3:CD007654. doi:10.1002/14651858.CD007654.pub4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/26934640/pubmed" id="26934640" target="_blank">26934640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16808550">
<a name="16808550"></a>Slørdal L, Spigset O. Heart failure induced by non-cardiac drugs. <i>Drug Saf</i>. 2006;29(7):567-586. doi:10.2165/00002018-200629070-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/16808550/pubmed" id="16808550" target="_blank">16808550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23076689">
<a name="23076689"></a>Tobbia P, Norris LA, Klima LD. Ventricular fibrillation coinciding with phentermine initiation. <i>BMJ Case Rep</i>. 2012;2012:bcr2012006410. doi:10.1136/bcr-2012-006410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/23076689/pubmed" id="23076689" target="_blank">23076689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11834685">
<a name="11834685"></a>Tomita T, Zhao Q. Autopsy findings of heart and lungs in a patient with primary pulmonary hypertension associated with use of fenfluramine and phentermine. <i>Chest</i>. 2002;121(2):649-652. doi:10.1378/chest.121.2.649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/11834685/pubmed" id="11834685" target="_blank">11834685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32753461">
<a name="32753461"></a>Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. <i>CMAJ</i>. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/32753461/pubmed" id="32753461" target="_blank">32753461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24231879">
<a name="24231879"></a>Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. <i>JAMA</i>. 2014;311(1):74-86. doi:10.1001/jama.2013.281361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/24231879/pubmed" id="24231879" target="_blank">24231879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9714271">
<a name="9714271"></a>Zimmer JE, Gregory RJ. Bipolar depression associated with fenfluramine and phentermine. <i>J Clin Psychiatry</i>. 1998;59(7):383-384. doi:10.4088/jcp.v59n0707e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phentermine-drug-information/abstract-text/9714271/pubmed" id="9714271" target="_blank">9714271</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9765 Version 470.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
